Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Vital-Net Happy about Tie-up with Toho and Other Wholesalers
June 6, 2005
- Alfresa HD: Profits Slip Despite Growth in Sales
June 6, 2005
- Vfend and 8 Other Drugs Recommended for Approval
June 6, 2005
- Suzuken Aims for Domestic Market Share of 25% by 2010
June 6, 2005
- 18th INTERPHEX JAPAN
June 6, 2005
- NEW PRODUCTS
June 6, 2005
- BUSINESS NEWS IN BRIEF
June 6, 2005
- MEDICAL DEVICE NEWS IN BRIEF
June 6, 2005
- Zeria: Strong Consumer Health Sales Offset Drop in Ethical Sales
June 6, 2005
- JACDS Proposes New OTC Drug-Selling Professionals
June 6, 2005
- Fuso: Sales, Profits Up Despite Lower Sales of Kindaly
June 6, 2005
- R&D NEWS IN BRIEF
June 6, 2005
- Nikken Chemicals: Profits Up Sharply Despite Lower Sales
June 6, 2005
- NEW PRODUCTS
June 6, 2005
- Teikoku Hormone: Profits Up Despite Slight Dip in Sales
June 6, 2005
- REGULATORY NEWS IN BRIEF
June 6, 2005
- Yakult Honsha: Pharma Div. Sees 2.1% Decline in Sales
June 6, 2005
- Kobayashi: Sales Up 1.9% at \215,708 Mil.
June 6, 2005
- Seikagaku Corp.: 8.8% Increase in Sales to \22,564 Mil.
June 6, 2005
- Mediceo HD: Sales Rise 29.7% to \1,665,815 Mil.
June 6, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…